Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies-Reference-Cited by-同舟云学术

Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies

Published:2021-12-03 Issue: Volume: Page:
ISSN:1933-7213
Container-title:Neurotherapeutics
language:en
Short-container-title:Neurotherapeutics

Author:

Capone Fioravante^ORCID,Lucchini Matteo,Ferraro Elisabetta,Bianco Assunta,Rossi Mariagrazia,Cicia Alessandra,Cortese Antonio,Cruciani Alessandro,De Arcangelis Valeria,De Giglio Laura,Motolese Francesco,Sancetta Biagio,Mirabella Massimiliano,Di Lazzaro Vincenzo

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Neurology (clinical),Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s13311-021-01165-9.pdf

Reference29 articles.

1. [https://covid19.who.int] accessed on 18 Aug 2021.

2. Ahammad I, Lira SS. Designing a novel mRNA vaccine against SARS-CoV-2: an immunoinformatics approach. Int J Biol Macromol. 2020;162:820–37. https://doi.org/10.1016/j.ijbiomac.2020.06.213.

3. Centonze D, Rocca MA, Gasperini C, Kappos L, Hartung HP, Magyari M, et al. Disease-modifying therapies and SARS-CoV-2 vaccination in multiple sclerosis: an expert consensus. J Neurol 2021;1–8. https://doi.org/10.1007/s00415-021-10545-2.

4. Ehde DM, Roberts MK, Herring TE, Alschuler KN. Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States. Multiple sclerosis and related disorders. 2021;49: 102788. https://doi.org/10.1016/j.msard.2021.102788.

5. Serrazina F, Pinho AS, Cabral G, Salavisa M, Correia AS. Willingness to be vaccinated against COVID-19:an exploratory online survey in a Portuguese cohort of multiple sclerosis patients. Multiple sclerosis and related disorders. 2021;51: 102880. https://doi.org/10.1016/j.msard.2021.102880.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study;BMC Neurology;2024-08-20

2. Humoral immune response and safety of Sars-Cov-2 vaccine in people with multiple sclerosis;BMC Immunology;2024-06-19

3. Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis;Journal of the Neurological Sciences;2024-01

4. Safety of SARS-CoV-2 vaccine in patients with autoimmune neurological conditions: A systematic review and meta-analysis;Heliyon;2024-01

5. Humoral and T-cell response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients: Correlations with DMTs and clinical variables;Neurotherapeutics;2023-12